SummaryA country-specific FRAX model has been developed for the Ukraine to replace the Austrian model hitherto used. Comparison of the Austrian and Ukrainian models indicated that the former markedly overestimated fracture probability whilst correctly stratifying risk.IntroductionFRAX has been used to estimate osteoporotic fracture risk since 2009. Rather than using a surrogate model, the Austrian version of FRAX was adopted for clinical practice. Since then, data have become available on hip fracture incidence in the Ukraine.MethodsThe incidence of hip fracture was computed from three regional estimates and used to construct a country-specific FRAX model for the Ukraine. The model characteristics were compared with those of the Austrian FRAX model, previously used in Ukraine by using all combinations of six risk factors and eight values of BMD (total number of combinations =512).ResultsThe relationship between the probabilities of a major fracture derived from the two versions of FRAX indicated a close correlation between the two estimates (r > 0.95). The Ukrainian version, however, gave markedly lower probabilities than the Austrian model at all ages. For a major osteoporotic fracture, the median probability was lower by 25% at age 50 years and the difference increased with age. At the age of 60, 70 and 80 years, the median value was lower by 30, 53 and 65%, respectively. Similar findings were observed for men and for hip fracture.ConclusionThe Ukrainian FRAX model should enhance accuracy of determining fracture probability among the Ukrainian population and help to guide decisions about treatment. The study also indicates that the use of surrogate FRAX models or models from other countries, whilst correctly stratifying risk, may markedly over or underestimate the absolute fracture probability.

Objectives. Osteoporosis, in addition to its consequent fracture burden, is a common and costly condition. FRAX® is a well-established, validated, web-based tool which calculates the 10-year probability of fragility fractures. A FRAX model for Ukraine has been available since 2016 but its output has not yet been translated into intervention thresholds for the treatment of osteoporosis in Ukraine; we aimed to address this unmet need in this analysis. Methods. In a referral population sample of 3790 Ukrainian women, 10-year probabilities of major osteoporotic fracture (MOF) and hip fracture separately were calculated using the Ukrainian FRAX model, with and without femoral neck bone mineral density (BMD). We used a similar approach to that first proposed by the UK National Osteoporosis Guideline Group, whereby treatment is indicated if the probability equals or exceeds that of a woman of the same age with a prior fracture. Results. The MOF intervention threshold in females (the age-specific 10-year fracture probability) increased with age from 5.5% at the age of 40 years to 11% at the age of 75 years where it plateaued and then decreased slightly at age 90 (10%). Lower and upper thresholds were also defined to determine the need for BMD, if not already measured; the approach targets BMD measurements to those at or near the intervention threshold. The proportion of the referral populations eligible for treatment, based on prior fracture or similar or greater probability, ranged from 44% to 69% depending on age. The prevalence of the previous fracture rose with age, as did the proportion eligible for treatment. In contrast, the requirement for BMD testing decreased with age. Conclusions. The present study describes the development and application of FRAX-based assessment guidelines in Ukraine. The thresholds can be used in the presence or absence of access to BMD and optimize the use of BMD where access is restricted.

Background. Nowadays, FRAX® algorithm is an informative method for evaluation of the risk of osteoporotic fractures, implemented in European and American guidelines for osteoporosis management. However, there are differences in "intervention thresholds" for antiosteoporotic treatment, which depend on the country, the model of health care system and the reimbursement for treatment. Ukrainian version of FRAX appeared in Ukraine in 2016, but the thresholds for intervention have not yet been developed. The purpose of the study was to determine the "thresholds" for the pharmacological treatment of osteoporosis and for additional diagnostic examination of Ukrainian population using national FRAX model. Materials and methods. 3790 outpatients aged 40-90 years (mean age 61.9 ± 10.0 years) were examined. The development of the "thresholds" for intervention and additional assessment of the bone using dual-energy X-ray densitometry (DXA) based on the methodology adopted by the Natio nal Osteoporosis Guideline Group in UK, which is further used in European guidelines. Results. There was an increase of the "thre shold" for pharmacological intervention ("upper threshold") with age from 6.6 % at the age of 40 to 13 % at the age of 75-85 years. The "lower threshold" (threshold for additional examination) increased significantly from 2.4 % at the age of 40 to 6.9 % in wo men aged 85 years. The evaluation strategy begins with an analysis of the history of low-traumatic fracture. In its presence, a decision to start antiosteoporotic treatment without DXA should be made. In patients without history of fracture, calculation of fracture risk according to FRAX is required. When the risk exceeds the limit of the "upper threshold" antiosteoporotic treatment without DXA is recommended, when its values below the limit of "lower thre shold" -additional examination or treatment is not required. In case of intermediate risk of fracture a DXA should be conducted with a reassessment of fracture risk and management tactics. Conclusions. The effectiveness of FRAX principles which uses in European guideline, but with particularities of the epidemiology of osteoporotic fractures in Ukraine, has been proved. Although this approach is cost-effective in other countries, its use in Ukraine may differ and may need to be further explored with an economic assessment of costs and benefits.

Data from previous studies demonstrate the high frequency of deficiency and insufficiency of vitamin D in Ukraine, as in the world, which varies depending on the age and gender of the population, the season, the region of residence, and the type of concomitant pathology. The purpose of the study was to assess the vitamin D status in the Ukraine population during 2016-2022 years depending on age, sex, month, and year of observation. In a single-center cohort study, serum 25-hydroxyvitamin D (25(OH)D) level was analyzed in 7105 subjects aged 20-99 years. The analysis was performed depending on age, sex, month, and year of observation. The mean serum 25(OH)D level in the total group was 30.9 [22.1-41.0] ng/ml, the lowest level was in the age group 90-99 years old and the highest one was in the subjects aged 40-69 years old. 52.7% of the subjects had a sufficient vitamin D level, 27.4% had insufficiency, and 19.9% had a deficiency of vitamin D. No gender differences were found in the serum level of 25(OH)D, except the one for the women aged 60-69 years old, who had higher vitamin D levels compared to males parameters. Seasonal 25(OH)D levels variations indicated the highest values in September and October and the lowest ones in February and March. Additionally, we established the increase of serum 25(OH)D from 2016 to 2021 with the highest values in 2020 and 2021. Our data confirmed a decrease in vitamin D deficiency and insufficiency in 2021 and 2022 in the Ukrainian population compared to previous years (2016-2019) and previous studies in the Ukrainian population while maintaining their age-related and seasonal characteristics. It may be associated with an improvement in public awareness of global vitamin D deficiency and its positive skeletal and extraskeletal effects, as well as the COVID-19 pandemic in recent years.